Contribution By Ojaswita Kutepatil
Siemens Healthineers AG, a Germany-based medical technology company, has reportedly been selected by Quest Diagnostics as the preferred supplier for its immunoassay testing with Atellica® Solution. Sources cite that once fully realized, this would b
Evonik, the leading chemicals group based in Germany, has reportedly agreed to the key terms of a €3 billion (approx. $3.4 billion) deal for selling its methacrylates plastics business to Advent International, a year after it decided to shed the un
The Government of Italy is reportedly formulating a legislation that could potentially lead to a merger of the network of Telecom Italia – an Italian telecommunications company – and its smaller rival, Open Fiber.
Sources familiar to the
Once one of the GRIDSERVE sites is constructed, it will serve as a blueprint for other solar farm developers in the UK.
UK-based GRIDSERVE has reportedly announced the construction of a 37.4-MW (megawatts) solar farm and a 27-MW battery storage pr
Reports indicate that a study being presented at the recently commenced annual meeting of the Society of Mining, Metallurgy and Exploration would be demonstrating a new carbon dioxide scrubber which could extract carbon dioxide more cost-effectively
Reports confirm that Haldor Topsøe, a global leader in electrolysis and production of ammonia, is leading a new research project to explore the potential of ammonia as a CO2-free fuel to be used instead of gasoline, fuel oil and diesel.
BNP Paribas SA and Standard Chartered Plc are among the handful of banks which would probably be added as co-managers for the landmark international bond sale of Saudi Aramco, stated sources with the knowledge of the matter.
Two Japan based lender
Global engineering and technology giant Emerson and HID Global®, a leading provider of trusted identity solutions, have recently announced that the companies have entered into a strategic partnership for enhancing monitoring capabilities which assis
The Janssen Pharmaceutical Companies has recently confirmed that the Drug Safety and Risk Management Advisory Committee and Psychopharmacologic Drug Advisory Committee of the U.S. FDA have jointly voted that the benefit-risk profile of SPARAVATOTM (e